|
cancer |
25 |
|
non-small cell lung cancer |
12 |
|
qigong |
12 |
|
quality of life |
12 |
|
chemoradiotherapy |
11 |
|
chemotherapy |
11 |
|
assessment |
10 |
|
breast cancer |
10 |
|
frailty |
10 |
|
nasopharyngeal carcinoma |
10 |
|
neoadjuvant therapy |
10 |
|
plasma ebv dna |
10 |
|
targeted therapy |
10 |
|
older adults |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
survival prediction |
9 |
|
treatment |
9 |
|
chinese |
8 |
|
intensity-modulated radiation therapy |
8 |
|
non-metastatic |
8 |
|
oesophageal cancer |
8 |
|
oesophageal squamous cell carcinoma |
8 |
|
oesophagectomy |
8 |
|
prognostic factors |
8 |
|
radiotherapy |
8 |
|
-depression |
7 |
|
cancer survivors |
7 |
|
cancer-related distress |
7 |
|
distress |
7 |
|
health-related quality of life |
7 |
|
illness perception |
7 |
|
insomnia |
7 |
|
long-term cancer survivors |
7 |
|
occupation |
7 |
|
physical activity |
7 |
|
randomised controlled trial |
7 |
|
return to work |
7 |
|
sleep disturbance |
7 |
|
sleep quality |
7 |
|
sleep trajectory |
7 |
|
thyroid cancer |
7 |
|
work productivity |
7 |
|
androgen receptor |
6 |
|
bq323636.1 |
6 |
|
concurrent chemoradiotherapy |
6 |
|
deficit accumulation |
6 |
|
follow up |
6 |
|
frailty phenotype |
6 |
|
health care |
6 |
|
immunotherapy |
6 |
|
local clinical remission |
6 |
|
metastatic |
6 |
|
older cancer patients |
6 |
|
positron emission tomography |
6 |
|
post-treatment plasma ebv dna |
6 |
|
prognostic factor |
6 |
|
stomach neoplasms |
6 |
|
survivorship |
6 |
|
tamoxifen resistance |
6 |
|
5-fluorouracil |
5 |
|
acupressure |
5 |
|
aetiology |
5 |
|
canagliflozin |
5 |
|
capecitabine |
5 |
|
cetuximab |
5 |
|
chemotherapy-induced peripheral neuropathy |
5 |
|
covid-19 |
5 |
|
dapagliflozin |
5 |
|
drug repurposing |
5 |
|
eq-5d-5 l |
5 |
|
esophageal cancer |
5 |
|
gastric cancer |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
medical sciences |
5 |
|
metastatic brain tumours |
5 |
|
metastatic colorectal cancer |
5 |
|
metronomic |
5 |
|
oral cyclophosphamide |
5 |
|
palliative |
5 |
|
psychometric properties |
5 |
|
radiation therapy |
5 |
|
radiology and nuclear medicine |
5 |
|
randomized controlled trial |
5 |
|
recurrent |
5 |
|
reliability |
5 |
|
responsiveness |
5 |
|
sodium-glucose co-transporter 2 inhibitor |
5 |
|
surgery |
5 |
|
systemic treatment |
5 |
|
thypro-39 |
5 |
|
tyrosine kinase inhibitor |
5 |
|
validity |
5 |
|
acceptance |
4 |
|
antithyroid drugs |
4 |
|
anxiety |
4 |
|
cisplatin |
4 |
|
cognitive frailty |
4 |
|
cognitive function |
4 |
|
esophageal squamous cell carcinoma |
4 |
|
esophagectomy |
4 |
|
geriatric oncology |
4 |
|
graves’ disease |
4 |
|
hope |
4 |
|
hypothyroidism |
4 |
|
immune checkpoint inhibitor |
4 |
|
immune checkpoint inhibitors |
4 |
|
immune-related endocrine dysfunction |
4 |
|
malignancy |
4 |
|
neoplasm metastasis |
4 |
|
older cancer survivors |
4 |
|
population based cohort |
4 |
|
prediction |
4 |
|
radioactive iodine |
4 |
|
resilience |
4 |
|
s-1 (combination) |
4 |
|
social support |
4 |
|
squamous cell carcinoma |
4 |
|
symptom |
4 |
|
target therapy |
4 |
|
thyroidectomy |
4 |
|
toxicities |
4 |
|
vaccination |
4 |
|
adverse events |
3 |
|
anastrozole |
3 |
|
ar antagonist |
3 |
|
aromatase inhibitor resistance |
3 |
|
brachytherapy |
3 |
|
ccrk |
3 |
|
cct241533 |
3 |
|
cervical esophageal cancer |
3 |
|
chk2 |
3 |
|
chk2 inhibitor |
3 |
|
cognition |
3 |
|
communication |
3 |
|
cxcr1 |
3 |
|
depression |
3 |
|
digital rehabilitation |
3 |
|
direct medical costs |
3 |
|
dna damage |
3 |
|
doxorubicin resistance |
3 |
|
dysphagia |
3 |
|
geriatric assessment |
3 |
|
hormonal therapy |
3 |
|
intensity modulated radiotherapy |
3 |
|
interleukin-8 |
3 |
|
ku70 |
3 |
|
laryngeal preservation |
3 |
|
mobile app-based intervention |
3 |
|
nhej |
3 |
|
novel target |
3 |
|
oestrogen receptor |
3 |
|
older people |
3 |
|
palliative care |
3 |
|
prediction models |
3 |
|
srpk1 |
3 |
|
srsf5 |
3 |
|
survivor |
3 |
|
systematic review |
3 |
|
terminal care |
3 |
|
tma |
3 |
|
type 2 diabetes mellitus |
3 |
|
68ga |
2 |
|
adenocarcinoma |
2 |
|
adjuvant radiotherapy |
2 |
|
advanced gastric adenocarcinoma |
2 |
|
airway obstruction |
2 |
|
carcinoma, adenoid cystic |
2 |
|
case conference |
2 |
|
colorectal cancer |
2 |
|
community-based palliative care |
2 |
|
conformal radiotherapy |
2 |
|
dota |
2 |
|
geriatrics |
2 |
|
gpt-4 |
2 |
|
immune checkpoint inhibition (ici) |
2 |
|
induction chemotherapy |
2 |
|
intensity-modulated radiotherapy |
2 |
|
maintenance |
2 |
|
management |
2 |
|
metastasis |
2 |
|
microsatellite instability (msi) |
2 |
|
mobile applications |
2 |
|
neuroendocrine tumors |
2 |
|
oncology |
2 |
|
patient-reported outcome measures |
2 |
|
pd-l1 |
2 |
|
peptide receptor radionuclide therapy |
2 |
|
pet/ct |
2 |
|
self-management |
2 |
|
telemedicine |
2 |
|
trachea |
2 |
|
tumor mutational burden (tmb) |
2 |
|
volumetric modulated arc therapy |
2 |
|
advanced breast cancer |
1 |
|
anesthesiology |
1 |
|
anthracycline |
1 |
|
breast cancer specific survival |
1 |
|
breathlessness |
1 |
|
capecitabinecy |
1 |
|
cardiopulmonary resuscitation |
1 |
|
clinical trials |
1 |
|
clophosphamide |
1 |
|
computer-assisted |
1 |
|
delivery of healthcare |
1 |
|
do not resuscitate |
1 |
|
docetaxel |
1 |
|
dyspnea |
1 |
|
early breast cancer |
1 |
|
end of life care |
1 |
|
ethics |
1 |
|
global health |
1 |
|
imaging |
1 |
|
metastatic disease |
1 |
|
multidisciplinary |
1 |
|
older patients |
1 |
|
overall survival |
1 |
|
palliative medicine |
1 |
|
pandemics |
1 |
|
pathology |
1 |
|
pertuzumab |
1 |
|
radiation dosage |
1 |
|
radiotherapy planning |
1 |
|
san antonio breast cancer symposium |
1 |
|
scientific conference |
1 |
|
three-dimensional |
1 |
|
triple negative breast cancer |
1 |
|
uterine cervical neoplasms |
1 |
